BioCardia, Inc. plans to submit its CardiAMP therapy for regulatory approval in Japan during the next quarter [2].
The move marks a critical step in the company's effort to expand its cardiac therapy into international markets while managing operational costs.
During an earnings call on Aug. 12 [3], the company discussed financial results for the quarter ended June 30 [4]. BioCardia reported that net cash used in operations for the second quarter was approximately $1.7 million [1]. For the first half of 2026, the total net cash used in operations reached approximately $3.4 million [1].
President and CEO Peter A. Altman focused on the upcoming regulatory milestones for the company's lead therapy. The company is preparing for the Shonin regulatory submission in Japan, which is the formal application process for pharmaceutical and medical device approval.
"We are preparing for the Shonin regulatory submission in Japan next quarter, with approval approximately 12 months after we submit," Altman said [2].
While some reports highlighted regulatory wins in both Japan and the U.S., the company's leadership said that the Japanese approval process is expected to take roughly one year following the submission [2]. The company continues to operate from its headquarters in Sunnyvale, California, as it pursues these global regulatory goals.
BioCardia's financial reports indicate a trend of narrowed losses as the firm moves toward these submission deadlines. The company's focus remains on the clinical and regulatory progress of CardiAMP to secure a foothold in the Japanese healthcare market.
“Approval is expected approximately 12 months after we submit.”
BioCardia is transitioning from a purely developmental phase to a regulatory execution phase in Asia. By targeting the Japanese market via the Shonin process, the company is seeking to diversify its revenue potential and validate its therapy outside the U.S. regulatory environment. The narrowing of operational losses suggests a tightening of fiscal discipline as the company awaits the lengthy 12-month approval window in Japan.
